Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04667715
Other study ID # BT011
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date December 2024
Est. completion date June 2026

Study information

Verified date March 2024
Source InSightec
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of using the Exablate Type 2 system using microbubble resonators (Exablate Test Arm) to disrupt the Blood-Brain Barrier for the purpose of temporarily transforming, and thereby 'marking', regions of infiltrating gliomas prior to planned surgical resection, for the purpose of improving tumor visualization during the surgery to achieve a greater proportion of subjects who receive a Gross Total Resection (GTR) per plan compared to those not undergoing a BBBD procedure prior to resection (Control Arm).


Description:

After being informed about the study and potential risks, all patients giving written informed consent will undergo screening to determine eligibility for study entry. Patients who meet the eligibility requirements will be randomized in a 2:1 ratio to Exablate Test Arm and to Control Arm, respectively. The following assessments will occur: 1. Pre-surgical planning and Post-surgical visit MRI exams with and without contrast will be collected for evaluation by the study core lab; Any return to surgery for additional resection will be captured 2. All subjects will be seen at ~Week 2, and ~4-Weeks post resection for physical and neurological exams and to assess for complications or adverse events. These visits should coincide with standard (Neuro-oncology) care following resection. 3. Long-term outcomes will be collected during standard of care Neuro-oncology care follow-up visits for up to 2 years post resection; standard of care MRIs and RANO assessments will be collected.


Recruitment information / eligibility

Status Suspended
Enrollment 120
Est. completion date June 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years to 85 Years
Eligibility Inclusion Criteria: 1. Male or Female between 21-85 years of age who are able and willing to give informed consent 2. Subjects with suspected Grade II, III or IV infiltrating glioma (IG) on pre-operative brain imaging scans who have a non-enhancing component and are planned for surgical resection. 3. Karnofsky Performance Score 70-100 4. Able to communicate sensations during the Exablate BBBD procedure Exclusion Criteria: 1. Tumor originating from the deep midline, thalamus, midbrain, cerebellum or brainstem. 2. Multifocal tumors 3. MRI or clinical findings of: 1. Active or chronic infection(s) or inflammatory processes 2. Acute or chronic hemorrhages, specifically any lobar microbleeds, and no siderosis, amyloid angiopathy, or macro-hemorrhages 3. Intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis 4. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp 5. MR non-compatible metallic implants in the skull or the brain or the presence of unknown MR unsafe devices 6. Significant cardiac disease or unstable hemodynamic status 1. Documented myocardial infarction within six months of enrollment 2. Unstable angina on medication 3. Unstable or worsening congestive heart failure 4. Left ventricular ejection fraction below the lower limit of normal 5. History of a hemodynamically unstable cardiac arrhythmia 6. Cardiac pacemaker 7. Patient has right-to-left, bidirectional, or transient right-to-left cardiac shunts 8. Subjects with relative contraindications to perflutren including subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation, 9. Perflutren sensitivity or allergy ii. QT prolongation observed on screening ECG (QTc > 450 for men and >470 for women) 7. Uncontrolled hypertension (systolic > 180 and diastolic BP > 120 on medication) 8. Unable to discontinue use of anti-coagulant/antiplatelet therapy as per local standard. 9. History of a liver disease, bleeding disorder, coagulopathy or a history of spontaneous hemorrhage or evidence of increased risk of bleeding 10. Abnormal coagulation profile (Platelets < 80,000), PT (>14) or PTT (>36), and INR > 1.3. 11. Large lacunar lesions that cannot be navigated around 12. Known cerebral or systemic vasculopathy 13. Significant depression and at potential risk of suicide 14. Known sensitivity/allergy to gadolinium, or other intravascular contrast agents 15. Active seizures despite medication treatment (defined as >1 seizure per week) which could be worsened by disruption of the blood brain barrier 16. History of anaphylactic shock 17. Active drug or alcohol disorder which have a higher risk for seizures, infection and/or poor executive functioning 18. Positive HIV status, which can lead to increased entry of HIV into the brain parenchyma leading to HIV encephalitis 19. Potential blood-borne infections which can lead to increased entry to brain parenchyma leading to meningitis or brain abscess 20. Any contraindications to MRI scanning, 21. Impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 22. Severe Respiratory Illness 23. Currently in a clinical trial involving an investigational product or non-approved use of a drug or device 24. Pregnancy or Lactation

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Exablate BBBD
Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators

Locations

Country Name City State
United States University of Maryland Baltimore Maryland
United States The University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation of circulating tumor biomarkers Collection of blood for evaluation of circulating tumor biomarkers (e.g. circulating tumor DNA [ctDNA]) pre- and post-BBBD procedure
Primary Overall safety of the Exablate BBBD procedure itself as measured through the collection of adverse events Safety of the Exablate BBBD procedure will be evaluated by patient examination and post-procedure MRI exams assessing changes in the treated region. Adverse events will be reported by the Investigator and monitored in both treatment arms. Approximately 2 months
Primary Effectiveness of BBBD as determined by the proportion of subjects in whom a GTR is acheived The proportion of subjects in whom a gross total resection (actual versus planned) is achieved as measured on post-operative imaging compared to pre-resection imaging MRI 72 hours post resection
Secondary Confirmation of accuracy of Exablate BBBD targeting Confirmation that new BBBD by contrast enhancement in a previously non-enhancing area overlies the intended target for BBBD. (ExAblate arm only) MRI immediately after the ExAblate procedure
Secondary Return Rate for Second Surgery for Completion of Resection Comparison of the Return Rate between the two treatment arms. Approximately 2 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04539574 - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors N/A
Enrolling by invitation NCT04461002 - Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Completed NCT03242824 - The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma Phase 2
Recruiting NCT04186832 - Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy N/A
Completed NCT00424554 - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) Phase 2
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT02805179 - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma Phase 2
Terminated NCT04556929 - Enhanced Detection in Glioma Excision N/A
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Recruiting NCT06043232 - MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Not yet recruiting NCT06043765 - Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training N/A
Not yet recruiting NCT05025969 - Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Completed NCT02978261 - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas Phase 1
Terminated NCT01502605 - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas Phase 1
Completed NCT01836536 - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients N/A
Completed NCT01479686 - iMRI Guided Resection in Cerebral Glioma Surgery Phase 3
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Not yet recruiting NCT00977327 - Comparison of Neuro-navigational Systems for Resection-Control of Brain Tumors N/A